“There’s a huge misconception that everything in cannabis is the same, and every company in cannabis is doing the same thing,” says Aras Azadian, CEO of Avicanna (TSX: AVCN) (OTCQX: AVCNF), a Toronto-based cannabinoid and biopharmaceutical company.
The exec believes that investors first need to understand that “just because a company is working with cannabinoids, that doesn’t make it part of the same sector, same industry or same metrics.”
A vivid discussion about cannabis, cannabinoids and industry categories fired up at the Benzinga Cannabis Capital Conference on Thursday.
Azadian, along with Stephen Dahmer, CMO of Vireo Health (CSE: VREO) (OTCQX: VREOF), Jon Vaught, CEO of Front Range Biosciences and Joe Feltham, COO of 4Front Ventures (CSE: FFNT) (OTCQX: FFNTF) shared their comments on how understanding the basic science behind the plant can be a crucial card in the deck of any investor interested in the cannabis space.
ACS Laboratory CEO Roger Brown led the panel.
The Cannabis Industry Encompasses Many Sectors: “Right now we talk about ‘cannabis research’ or ‘cannabis’ as such a general term. What are we talking about? There are a thousand different products on the market. Standardization of what we call ‘cannabis’ …